Skip to main content
Publications
Domenech E, Fortuny J , Martinez D , Tormos A , Huang Z, Hill D, Weinstein C, Esslinger S, Krumme A, Mines D, Gisbert J. A post-authorization safety study of golimumab in ulcerative colitis using the Spanish ENEIDA registry (MK8259-042) . Poster presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.
Ahmadizar F, Fortuny J , Royo AC, Plana E , Weinrib R , Garcia Esteban R , Boric K , Yefimenko N, Haugh M, Carreras JJ, Urchueguia-Fornes A, Correcher E, van den Berg JM, Lysen T, Villalobos F, Bissacco CA, Newbern EC, Willame C, Praet N, Sturkenboom MCJM. Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European healthcare data sources: methods and results of the second study feasibility assessment . Poster presented at the 2024 ISPE Annual Meeting; August 27, 2024. Berlin, Germany.
Weinrib R , Fortuny J , Martinez D , Kollhorst B, Haug U, Kousholt A, Ehrenstein V, Iversen P, Mortensen J, Bosch D, Kuppen M, Pisa F, Vassiley Z. Drug utilisation of radium-223 under routine clinical practice (DIRECT) in Europe: a post-authorisation safety study . Poster presented at the 2024 ISPE Annual Meeting; August 26, 2024. Berlin, Germany.
Ahmadizar F, Fortuny J , Cid-Royo A, Plana E , Weinrib R , Garcia Esteban R , Boric K , Yefimenko N, Carreras JJ, Urcheguia A, Correcher-Martinez E, Mira-Iglesias A, Swart KMA, van den Berg JM, Overbeek JA, Villalonos F, Bissacco CA, Newbern C, Praet N, Willame C, Sturkenboom M. Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European healthcare data: methods and results of the first study feasibility assessment . Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):189-90. doi: 10.1002/pds.5687
Sultana J, Crisafulli S, Almas M, Antonazzo IC, Baan E, Bartolini C, Bertuccio MP, Bonifazi F, Capuano A, Didio A, Ehrenstein V, Felisi M, Ferrajolo C, Fontana A, Francisca R, Fourrier-Reglat A, Fortuny J , Gini R, Hyeraci G, Hoeve C, Kontogiorgis C, Isgrò V, Lalagkas P, L'Abbate L, Layton D, Landi A, Narduzzi S, Pereira LR, Poulentzas G, Rafaniello C, Roberto G, Scondotto G, Sportiello L, Toma M, Toussi M, Verhamme K, Volpe E, Trifirò G. Overview of the European post-authorisation study register post-authorization studies performed in Europe from September 2010 to December 2018 . Pharmacoepidemiol Drug Saf. 2022 Jun;31(6):689-705. doi: 10.1002/pds.5413
Fortuny J , von Gersdorff G, Lassalle R, Linder M, Overbeek J, Reinold J, Toft G, Timmer A, Dress J, Blin P, Droz-Perroteau C, Ehrenstein V, Franzoni C , Herings R, Kollhorst B, Moore N, Odsbu I, Perez-Gutthann S , Schink T, Rascher K, Rasouliyan L, Rothman KJ , Saigi-Morgui N , Schaller M, Smits E, Forstner M, Intravenous Iron Consortium, Benichou J, Bircher AJ, Garbe E, Rampton DS, Gutierrez L . Use of intravenous iron and risk of anaphylaxis: a multinational observational post-authorisation safety study in Europe . Pharmacoepidemiol Drug Saf. 2021 Oct;30(10):1447-57. doi: 10.1002/pds.5319
Gutierrez L , Blin P, Dress J, Droz-Perroteau C, Ehrenstein V, Franzoni C , Kollhorst B, Lassalle R, Linder M, Moore N, Odsbu I, Overbeek J, Perez-Gutthann S , Schink T, Rascher K, Rasouliyan L, Reinold J, Rothman KJ , Saigi-Morgui N , Schaller M, Smits E, Timmer A, Toft G, von Gersdorff G, Intravenous Iron Consortium, Fortuny J . A multinational European study of anaphylaxis among recipients of intravenous iron . Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Gilsenan A , Fortuny J , Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Harding A , Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu E, Plana E , Ruigomez A, Schink T, Ziemiecki R , Andrews EB. Cardiovascular safety of prucalopride in patients with chronic constipation: a multinational population-based cohort study . Drug Saf. 2019 Oct;42(10):1179-90. doi: 10.1007/s40264-019-00835-0
Fortuny J , Gilsenan A , Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Plana E , Ruigomez A, Schink T, Ziemiecki R , Andrews EB. Study design and cohort comparability in a study of major cardiovascular events in new users of prucalopride versus polyethylene glycol 3350 . Drug Saf. 2019 Oct;47(10):1167-77. doi: 10.1007/s40264-019-00836-z
Gilsenan A , Fortuny J , Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Harding A , Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu I, Plana E , Ruigomez A, Schink T, Ziemiecki R , Andrews EB. Cardiovascular safety of prucalopride for chronic constipation: a multinational population-based cohort study . Presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):33. doi: 10.1002/pds.4864
Gutierrez L , Bezemer ID, Dress J, Ehrenstein V, Forstner M, Franzoni C , Lassalle R, Linder M, Droz-Perroteau C, Odsbu I, Overbeek JA, Perez-Gutthann S , Pisa FE, Rascher K, Rasouliyan L, Reinold J, Rothman KJ , Saigi-Morgui N , Schaller M, Smits E, Timmer A, Toft G, von Gersdorff G, Fortuny J . Challenges in conducting a multinational European study of severe hypersensitivity reactions among recipients of intravenous iron . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):640. doi: 10.1002/pds.4864
Fortuny J , Gilsenan AW , Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Plana E , Ruigomez A, Schink T, Ziemiecki R , Andrews EB. Cohort study of the relative incidence of major cardiovascular events among patients initiating prucalopride versus a matched comparator cohort in a multinational study: study design and comparability of cohorts . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):627. doi: 10.1002/pds.4864
Cainzos-Achirica M, Ruigomez A, MacDonald T, Garcia-Rodriguez L, Fortuny J , Flynn RW, Plana E , Ziemiecki R , Andrews EB, Gilsenan A . Validation of major cardiovascular events in a multi-database post-authorization safety study of prucalopride . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):331. doi: 10.1002/pds.4864
Margulis AV , Fortuny J , Kaye JA, Calingaert B , Reynolds M , Plana E , McQuay LJ, Jan Atsma W, Franks B, de Vogel S, Perez-Gutthann S , Arana A . Proportions of cancer cases in primary care, hospital, and cancer registry data among patients treated for overactive bladder. Letter to editor . Epidemiology. 2019 Mar;30(2):e8-9. doi: 10.1097/EDE.0000000000000953
Margulis AV , Fortuny J , Kaye JA, Calingaert B , Reynolds M , Plana E , McQuy LJ, Atsma WJ, Franks B, de Vogel S, Perez-Gutthann S , Arana A . Value of free-text comments for validating cancer cases using primary-care data in the United Kingdom . Epidemiology. 2018 Sep;29(5):e41-2.
Gilsenan A , Fortuny J , Plana E , Ruigomez A, Karlsson P, Flynn RWV, Cantero OF, Garcia-Rodriguez L, Linner L, Cainzos-Achirica M, Bartsch J , MacDonald T, Kieler H, Andrews EB. Non-interventional cohort study of the relative incidence of major cardiovascular events among patients initiating prucalopride versus a matched comparator cohort initiating polyethylene glycol 3350 (PEG) . Poster presented at the 2018 Digestive Disease Week; June 3, 2018. Washington, DC.
Margulis AV , Fortuny J , Kaye JA, Calingaert B , Reynolds M , Plana E , McQuay LJ, Atsma WJ, Franks B, de Vogel S, Perez-Gutthann S , Arana A . Validation of cancer cases using primary care, cancer registry, and hospitalization data in the UK . Epidemiology. 2018 Mar;29(2):308-13. doi: 10.1097/EDE.0000000000000786
Alford SH, Divine G, Chao C, Habel LA, Janakiraman N, Wang Y, Feigelson HS, Scholes D, Roblin D, Epstein MM, Engel L, Havstad S, Wells K, Yood MU, Fortuny J , Johnson CC, Cancer Research Network Lymphoma Study Group. Serum cholesterol trajectories in the 10 years prior to lymphoma diagnosis . Cancer Causes Control. 2018 Jan;29(1):143-56. doi: 10.1007/s10552-017-0987-7
Epstein MM, Divine G, Chao CR, Wells KE, Feigelson HS, Scholes D, Roblin D, Yood MU, Engel LS, Taylor A, Fortuny J , Habel LA, Johnson CC. Statin use and risk of multiple myeloma: an analysis from the Cancer Research Network . Int J Cancer. 2017 Aug 1;141(3):480-7. doi: 10.1002/ijc.30745
Margulis AV , Varas-Lorenzo C, Bui CL , McQuay LJ, Ziemiecki R , Reynolds M , Rebordosa C , Pladevall-Vila M , Fortuny J , Rivero-Ferrer E , Plana E , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S , Arana A . Validation of cardiovascular events and covariates in CPRD GOLD using questionnaires to general practitioners (GPS) . Presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):255-6.
McGrath LJ, Rulgomez A, Plana E , Fortuny J , Garcia-Rodriguez L, Rebordosa C , Varas-Lorenzo C, Ziemiecki R , Gilsenan AW , Andrews E. Characteristics of patients prescribed prucalopride versus an active comparator in England, Wales, and Northern Ireland . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):634.
Plana E , McGrath LJ, Fortuny J , Ruigomez A, Fernandez-Cantero O, Garcia-Rodriguez LA, Gilsenan AW , Andrews E, Rebordosa C , Ziemiecki R . An algorithm to identify duplicate patients when pooling aggregate data from two primary care databases in the United Kingdom . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):58-9. doi: 10.1002/pds
Fortuny J , Kaye JA, Bui CL , Gilsenan AW , Bartsch J , Plana E , McQuay LJ, Calingaert B , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez Gutthan S , Arana A , Margulis AV . Evaluation of free-text comments to validate common cancer diagnoses in the UK CPRD . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):58.
Avella-Garcia CB, Julvez J, Fortuny J , Rebordosa C , Garcia-Esteban R , Galan IR, Tardon A, Rodriguez-Bernal CL, Iniguez C, Andiarena A, Santa-Marina L, Sunyer J. Acetaminophen use in pregnancy and neurodevelopment: attention function and autism spectrum symptoms . Int J Epidemiol. 2016 Jun. doi: 10.1093/ije/dyw115
Schmiedl S, Fischer R, Ibanez L, Fortuny J , Thurmann P, Ballarin E, Ferrer P, Sabate M, Rottenkolber D, Gerlach R, Tauscher M, Reynolds R, Hasford J, Rottenkolber M. Tiotropium Respimat® vs. HandiHaler®: real-life usage and TIOSPIR trial generalizability . Br J Clin Pharmacol. 2016 Feb;81(2):379-88. doi: 10.1111/bcp.12808
Ferrer P, Sabate M, Ballarin E, Fortuny J , Rottenkolber M, Schmiedl S, Laporte JR, Ibanez L. Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007-2010 . Springerplus. 2015 Oct 15;4:612. doi: 10.1186/s40064
Rottenkolber M, Fischer R, Ibanez L, Fortuny J , Reynolds R, Amelio J, Gerlach R, Tauscher M, Thurmann P, Hasford J, Schmiedl S. Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial . BMC Pulm Med. 2015 May 6;15:55.
Schmiedl S, Fischer R, Ibanez L, Fortuny J , Klungel OH, Reynolds R, Gerlach R, Tauscher M, Thurmann P, Hasford J, Rottenkolber M. Utilisation and off-label prescriptions of respiratory drugs in children . PLoS One. 2014 Sep 2;9(9):e105110. doi: 10.1371/journal.pone.0105110
Rottenkolber M, Rottenkolber D, Fischer R, Ibáñez L, Fortuny J , Ballarin E, Sabaté M, Ferrer P, Thürmann P, Hasford J, Schmiedl S. Inhaled beta-2-agonists/muscarinic antagonists and acute myocardial infarction in COPD patients . Respir Med. 2014 Aug;108(8):1075-90.
Sabate M, Pacheco JF, Ballarín E , Ferrer P, Petri H, Hasford J, Schoonen MW, Rottenkolber M, Fortuny J , Laporte JR, Ibanez L. A compilation of research working groups on drug utilisation across Europe . BMC Res Notes. 2014;7:143.